TOI Oncology Institute, Inc.
8-K Current Report
Filed: February 23, 2026
Health Care
Services-Offices & Clinics of Doctors of MedicineOncology Institute, Inc. (TOI) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 5.02 · Departure/Election of Directors or Officers
- • Kimberly Tzoumakas appointed to TOI Board via unanimous written consent, effective Feb 23, 2026, filling existing vacancy
- • Cleared Nasdaq independence requirements; no committee assignments yet
Item 7.01 · Regulation FD Disclosure
- • Reg FD disclosure filed, but substantive content resides in the referenced exhibit — no financial figures or operational data included in the item text itself
- • Boilerplate liability disclaimer confirms disclosed information is not incorporated by reference into future filings unless explicitly stated
Other Oncology Institute, Inc. 8-K Filings
Get deeper insights on Oncology Institute, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.